Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)-Reference-Cited by-同舟云学术

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Published:2015-11-07 Issue:6 Volume:173 Page:1387-1399
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Paul C.¹,Cather J.²,Gooderham M.³,Poulin Y.⁴,Mrowietz U.⁵,Ferrandiz C.⁶⁷,Crowley J.⁸,Hu C.⁹,Stevens R.M.⁹,Shah K.⁹,Day R.M.⁹,Girolomoni G.¹⁰,Gottlieb A.B.¹¹

Affiliation:

1. Department of Dermatology Toulouse University Hôpital Larrey, 24 Chemin de Pouvourville Toulouse 31000 France

2. Modern Research Associates Dallas TX U.S.A.

3. Skin Centre for Dermatology Peterborough ON Canada

4. Centre de Recherche Dermatologique du Québec Métropolitain Québec QC Canada

5. Psoriasis Center at the Department of Dermatology University Medical Center Schleswig‐Holstein Campus Kiel Germany

6. University Hospital Germans Trias i Pujol Badalona Spain

7. Universidad Autónoma of Barcelona Barcelona Spain

8. Bakersfield Dermatology Bakersfield CA U.S.A.

9. Celgene Corporation Warren NJ U.S.A.

10. University of Verona Verona Italy

11. Tufts Medical Center Boston MA U.S.A.